Overweight and Obesity
Conditions
Keywords
protein, diet supplementation, children, insulin resistance, adiponectin/leptin, gut microbiota
Brief summary
The state of San Luis Potosí comprises several municipalities with diverse environmental conditions, ranging from semi-tropical to very arid zones. Arid zones have a high rate of childhood with obesity. This study aimed to investigate the effects of dietary supplementation with high-quality protein on the modulation of the gut microbiota.
Detailed description
Overweight and obesity are chronic diseases that result from complex interactions including genetics, environment, eating behaviors, and limited access to a healthy diet. Amaranth grains contain high-quality proteins (well balance of essential amino acids), with good biodigestibiliy. In addition, amaranth proteins contains encrypted peptides with several biological functions with health benefits, such as antihypertensive, antidiabetic, antioxidant, and antiobosegenic, but those activities have been reported in vitro assays and in vivo using mice models. In mice, have been reported the amaranth proteins were able to decrease the serum cholesterol and triglycerides levels and can modulate the gut microbiota. But until now, there are no studies evaluating the amaranth proteins in children with overweight and obesity and the modulation of gut microbiota. The work aimed to form a group of children aged 8-10 years with different Body Mass Index (BMI) which were allocated in groups as: normal weight (NW), overweight (OW), and with obesity (OB). Children received amaranth protein for 90 days, blood and feces were taken at the beginning and the end of the trial. Levels of fasting blood glucose, cholesterol, triglycerides, and insulin were analyzed. HOMA-IR and Adinopectin/Leptin ratio were calculated. Feces were used to analyze the metagenome and quantify the levels of Short Chain Fatty Acids (SCFAs). The study was aproved by the Research Ethics Committe of the Health Services San Luis Potosi (No. SLP/006-2018) and conducted in accordance with the Helsinki Declaration (2000). Informed assent was obtained from the participating children, and the informed consent from their parents or legal representatives.
Interventions
DIETARY_SUPPLEMENTAmProt (amaranth protein isolate)
Groups of children taken 2 g of amaranth protein isolate daily for 90 days
Sponsors
Instituto Potosino De Investigacion Cientifica Y Tecnologica AC
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Masking description
All parties involved, including participants and investigators, know which treatment is being administered
Intervention model description
A non-randomized pilot/trial implementation trial
Eligibility
Sex/Gender
ALL
Age
8 Years to 10 Years
Healthy volunteers
Yes
Inclusion criteria
* children who had not received antibiotics, prebiotics, or other drugs
Exclusion criteria
* children with other diseases and those who refused to sign informed consent form
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fecal DNA extraction and 16S rRNA gene sequencing sing the V4-V5 region of the 16S rRNA gene. | Samples were taken at the beginning and after 90 days | Number of ASVs in each analyzed group, alfa and beta diversity, ASVs abundance |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measurements of fecal Short Chain Fatty Acids (SCFAs) levels | Samples were taken at the beginning and after 90 days | Data of mg/g of acetic, propionic, butyric acids and total SCFAs |
| Hematological and biochemical serum analyses | 3 months | Table of glucose, cholesterol triglycerides, and cholesterol (mg/dL). ALT, ALP, GGT enzymes activities (U/L). Insulin, leptin (ng/mL). TNF-a, IL-1B, IL-6 (pg/mL) |
Countries
Mexico
Contacts
STUDY_DIRECTORMonica L Rangel Martinez, MD
Servicios de Salud de San Luis Potosi
Outcome results
None listed